Novartis Invests $23 Billion to Expand U.S. Manufacturing and R&D Infrastructure
Introduction:
Novartis has announced plans to invest $23 billion over the next five years to strengthen its infrastructure in the United States. The investment will ensure that all key medicines for US patients are manufactured domestically and will support a major expansion of the company’s operations across the country.
Features:
The initiative includes the construction of 10 new or expanded facilities, seven of which will be completely new. The company expects to create around 1,000 new roles at Novartis and contribute to approximately 4,000 additional jobs across the US. The expanded production capacity will cover active pharmaceutical ingredients (API), biologics, secondary production, and packaging.
Four new manufacturing facilities will be built in states yet to be confirmed. These will focus on biologics drug substances, drug products, device assembly, and packaging. One facility will produce chemical drug substances, oral solid dosage forms, and packaging. Two new radioligand therapy manufacturing facilities.
Novartis' strategic aim is to increase manufacturing in the country across its main therapeutic areas—oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic conditions. Once fully operational, the new facilities will enable Novartis to manufacture 100% of its key medicines within the US.
The new hub, expected to open between 2028 and 2029.
Specifications:
Name : Novartis
Year : 2028 and 2029
Type : Expansion
Budget : $23 Billion
